Prognostic impact of baseline left ventricular ejection fraction in patients with coronary chronic total occlusion after successful percutaneous coronary intervention or medical therapy: A prospective cohort study

基线左心室射血分数对冠状动脉慢性完全闭塞患者经皮冠状动脉介入治疗或药物治疗成功后的预后影响:一项前瞻性队列研究

阅读:1

Abstract

Left ventricular ejection fraction (LVEF) is a key determinant of prognosis in patients with coronary artery disease. However, the impact of LVEF categories on long-term outcomes in patients with coronary chronic total occlusion (CTO) remains underexplored. This study aimed to evaluate the 3-year clinical outcomes in CTO patients according to LVEF category. We retrospectively analyzed 1255 patients with coronary CTO, categorized into 3 groups based on LVEF: reduced (rEF, ≤40%), mildly reduced (mrEF, 41-49%), and preserved (pEF, ≥50%). The primary outcome was all-cause mortality. Secondary outcomes included cardiac death (CD), non-CD, myocardial infarction, and any revascularization, including target lesion revascularization (CTO vessels), target vessel revascularization (TVR and CTO vessels), and nontarget vessel revascularization (non-TVR and non-CTO vessels). After adjustment, all-cause mortality (P = .004 and P < .001, respectively) and CD (P = .005 and P < .001, respectively) were significantly higher in the rEF group compared with the mrEF and pEF groups. The mrEF group had significantly higher rates of any revascularization (P < .001), target lesion revascularization (CTO vessel, P = .024), and TVR (CTO vessel, P = .001) than the pEF group. These findings remained consistent even when the analysis was confined to patients who underwent percutaneous coronary intervention. In this single-center study of patients with coronary CTO, all-cause mortality was higher in the rEF group than in the mrEF and pEF groups, whereas no significant difference was observed between the mrEF and pEF groups. However, the mrEF group had a higher rate of any revascularization than the pEF group.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。